Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs JD.Com Inc (JD) Price & Performance

Charles River Laboratories Intl. IncTrade
JD.Com IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs JD.Com Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while JD.Com Inc trades at $29.39 (market cap $39.64B). The key difference: JD.Com Inc is far larger — about 3.6× Charles River Laboratories Intl. Inc's market cap, and JD.Com Inc pays a 3.47% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLJD
Market Cap
$11.14B$39.64B
Sector
HealthConsumer Cyclical
52-Week High
$233.60$36.17
52-Week Low
$145.57$25.19
Enterprise Value
$14.00B$25.80B
Dividend Yield
3.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

JD.Com Inc

JD.com trades at $28.88, up 2.41% today, with strong technical momentum and bullish analyst sentiment. Recent earnings beats and a consensus price target of $40 suggest significant upside potential. The company maintains robust revenue growth, reaching $1.31 trillion in 2025, though net margins compressed to 1.05%. Positive news highlights retail margin expansion and AI-driven investments.

Outlook remains favorable with Wall Street's 70% buy rating, but risks include Chinese regulatory scrutiny and ongoing margin pressures. The stock's current valuation at P/E 21.2 appears reasonable given growth prospects, though investors should monitor earnings sustainability and geopolitical factors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About JD.Com Inc

JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.

Read more on JD